United Therapeutics will spend approximately $477.6 million on an accelerated share repurchase, using the remainder of its $2 billion authorization and receiving approximately 719,376 shares initially. For investors, final share delivery will depend on average daily volume-weighted prices, while settlement may involve additional shares, cash, or shares delivered to Citibank.
Key Highlights
- The initial share delivery will represent approximately 75% of the total shares anticipated under the agreement.
- United Therapeutics previously repurchased an aggregate $1.5 billion through ASR agreements in March 2026.
- Final settlement is expected in the fourth quarter of 2026 and may involve additional shares or cash.
The agreement was entered into on September 8, with the upfront payment due on or around September 10 and final settlement expected in the fourth quarter of 2026.
719,376 Shares Delivered Initially
United Therapeutics (NASDAQ: UTHR) will receive approximately 719,376 shares of common stock at the start of the arrangement. The ultimate number of shares will be calculated using the average daily volume-weighted average price during the ASR term, less a discount and subject to contractual adjustments. At settlement, United Therapeutics may receive additional shares, or in limited circumstances pay cash to Citibank or elect to deliver shares.
$2 Billion Authorization Reaches Its Remainder
United Therapeutics previously entered ASR agreements covering an aggregate $1.5 billion of common stock in March 2026. After completing this additional repurchase, the company said it will have returned $4 billion to shareholders in approximately 2.5 years.
FAQs
Q: What is United Therapeutics buying back through the ASR?
A: United Therapeutics is repurchasing its common stock for approximately $477.6 million through an accelerated share repurchase agreement with Citibank. An initial delivery covers approximately 719,376 shares.
Q: When will United Therapeutics complete the share repurchase?
A: Final settlement of the United Therapeutics ASR is expected in the fourth quarter of 2026. The final share count will depend on average daily volume-weighted prices during the agreement.
Q: How does the UTHR ASR affect investors?
A: The agreement uses the remainder of United Therapeutics’ $2 billion authorization and initially returns shares to the company. Final settlement may provide additional shares or require cash or share delivery to Citibank.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.